登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell Grade Beads>DLL4 >MBS-C013

ActiveMax® Human DLL4 μBeads, premium grade (for cells) DMF

热销产品推荐:The Magnetic Stand (Cat.No. MB-01 & Cat.No. MB-02) can be used in conjunction with Beads.
ClinMaxTM细胞因子检测试剂盒

ProductSizeAmount
ActiveMax® Human DLL4 μBeads, premium grade (for cells)2.5 mg2.5 × 10⁷ beads
ActiveMax® Human DLL4 μBeads, premium grade (for cells)10 mg (2.5 mg × 4)1 × 10⁸ beads

背景(Background)

ActiveMax® Human DLL4 μBeads, premium grade (for cells) are produced under sterile manufacturing conditions (ISO 5) , and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.

表达区间及表达系统(Source)

ActiveMax® Human DLL4 μBeads, premium grade (for cells) are uniform, superparamagnetic beads of 5.5 µm with streptavidin on its surface and coupled with biotinylated Human DLL4 Protein, expressed from human 293 cells (HEK293) and contains AA Ser 27 - Pro 524 (Accession # NP_061947.1 ).

应用说明(Application)

ActiveMax® Human DLL4 μBeads, premium grade (for cells) can activate Notch signaling in hematopoietic stem/progenitor cells (HSPCs), mimicking DLL4+ epithelial cells in the thymus, and then drives T-lineage commitment and differentiation. It can be used for in vitro production of induced pluripotent stem cell derived T cells, such as inducing the differentiation from CD34+ cells to progenitor T cells to TCRαβ T cells in vitro, which provides a simple and robust tool to both study human T cell development and facilitate the development of engineered T cell therapies from renewable sources.

*We also carry ActiveMax® Streptavidin μBeads, premium grade (for cells)(Cat. No. MBS-C009),and it can be used for convenient preparation of your own sterile protein/antibody coupled beads for cell based assay, cell sorting and other applications. The ActiveMax® Streptavidin μBeads, premium grade can also be used together with other ActiveMax® μBeads, premium grade as Isotype control.

重构方法(Reconstitution)

See Certificate of Analysis (CoA) for detailed instruction.

存储(Storage)

This product is stable in storage under the following conditions: -20˚C for 12 months in lyophilized state. -70°C for 3 months under sterile conditions after reconstitution.

Please avoid repeated freeze-thaw cycles after reconstitution. Immediate use after reconstitution is highly recommended.

无菌(Sterility)

Negative

内毒素(Endotoxin)

Less than 0.002 EU per μg by the LAL method.

注意事项(Important Note)

This product is for research use only and not intended for therapeutic or in vivo diagnostic use.

制剂(Formulation)

Please contact us for detailed information.

Contact us for customized product form or formulation.

 

典型数据-Typical Data Please refer to DS document for the assay protocol.

DLL4 TYPICAL DATA

Assay of human DLL4 protein on the μBeads surface by Flow cytomtry.The human DLL4 conjugated on the μBeads (Cat. No. MBS-C013) surface were fluorescently stained using Human Anti-DLL4 Antibody, Mouse IgG1 and PE labeled anti-Mouse IgG1 Antibody, analyzed by flow cytometry (QC tested).

 

应用数据(Application Data)

DLL4 APPLICATION DATA

Combinations of ActiveMax® Human DLL4 μBeads (Cat. No. MBS-C013) and ActiveMax® Human VCAM-1 / CD106 μBeads (Cat. No. MBS-C019) could efficiently induce hematopoietic stem cells differentiation into CD56+ NK cells after 20 days of culture, with expression of CD56, NKp46, NKG2D, NKp30 and NKp44.

DLL4 APPLICATION DATA

The Cell Number of hcCD34P cells-derived CD7+ and CD5+ T-lymphoid progenitors After 21 Days of Culture. Combinations of ActiveMax® Human DLL4 μBeads, premium grade(for cells)(Cat.No.MBS-C013) and Cytokine could efficiently induce hcCD34P cells differentiation into CD7+ and CD5+ T-lymphoid progenitors after 21 days of culture.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
DLL4靶点信息
英文全称:Delta-like protein 4
中文全称:δ样蛋白-4
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:3详情
最高研发阶段:临床三期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定